Press release
-
Press Release
Automotive Dashcam Market worth $6.55 billion by 2033| MarketsandMarkets™
DELRAY BEACH, Fla., April 20, 2026 /PRNewswire/ — According to MarketsandMarkets™, the automotive dashcam market is projected to grow from USD…
Read More » -
Press Release
Guide Sets a New Standard for Industrial Thermography at Hannover Messe 2026
HANNOVER, Germany, April 20, 2026 /PRNewswire/ — On April 20, Hannover Messe 2026 officially opened at the Exhibition Grounds Hannover…
Read More » -
Press Release
SKYWORTH Dominates the 139th Canton Fair with Revolutionary OLED, RGB, and QD-MiniLED Smart TVs, Redefining Global Display Technology
GUANGZHOU, China, April 20, 2026 /PRNewswire/ — On April 15th, the 139th China Import and Export Fair (Canton Fair), co-hosted…
Read More » -
Press Release
IGT Appoints Mark Wadley Incoming President of Land-Based Gaming
Will Lead an Integrated, End-to-End Gaming Business Spanning Product, Commercial, and Operational Functions LAS VEGAS, April 20, 2026 /PRNewswire/ —…
Read More » -
SOLAI Limited Files 2025 Annual Report on Form 20-F
AKRON, Ohio, April 20, 2026 /PRNewswire/ — SOLAI Limited (NYSE: SLAI) (previously traded under “BTCM”) (“SOLAI” or the “Company”), a technology-driven…
Read More » -
Press Release
U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial Building on the existing…
Read More » -
Business Wire3 weeks ago
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
Applications are supported by the Phase 3 KEYNOTE-B15 results, which showed that KEYTRUDA plus Padcev demonstrated a statistically significant and…
Read More » -
Business Wire3 weeks ago
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
Applications are supported by the Phase 3 KEYNOTE-B15 results, which showed that KEYTRUDA plus Padcev demonstrated a statistically significant and…
Read More » -
Business Wire3 weeks ago
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
Applications are supported by the Phase 3 KEYNOTE-B15 results, which showed that KEYTRUDA plus Padcev demonstrated a statistically significant and…
Read More » -
Press Release
Milvus Robotics Introduces the SEIT F1500S Forklift-Type Autonomous Mobile Robot for Advanced Material Handling
ATLANTA, April 20, 2026 /PRNewswire/ — Milvus Robotics has officially introduced its latest advancement in industrial automation, the SEIT F1500S, a…
Read More »





